Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro

Developmental Biology

Volumn 233, Issue 2, 2001, Pages 526-536

  Genbacev, Olga ^a   Krtolica, Ana ^b   Kaelin, William ^c   Fisher, Susan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Cytotrophoblast; Fibronectin; HIF2 ; Human placenta; Hypoxia; pVHL

Indexed keywords

PROTEIN; PROTEIN HIF1ALPHA; PROTEIN HIF2ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL HYPOXIA; CELLULAR DISTRIBUTION; CYTOTROPHOBLAST; ENDOMETRIUM; FEMALE; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOTHER FETUS RELATIONSHIP; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

EID: 0035872881     PISSN: 00121606     EISSN: None     Source Type: Journal    
DOI: 10.1006/dbio.2001.0231     Document Type: Article

References (46)

1. Adelman D. M., Gertsenstein M., Nagy A., Simon M.C., Maltepe E. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev. 14:2000;3191-3203.
2. Almeida E. A. C., Ilic D., Han Q., Hauck C. R., Jin F., Kawakatsu H., Schlaepfer D. D., Damsky C. H. Matrix survival signaling: From fibronectin via focal adhesion kinase to c-Jun NH2-terminal kinase. J. Cell Biol. 149:2000;741-754.
3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. Burton G. J., Jauniaux E., Watson A. L. Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: The Boyd collection revisited. Am. J. Obstet. Gynecol. 181:1999;718-724.
5. Caniggia I., Mostachfi H., Winter J., Gassmann M., Lye S. J., Kuliszewski M., Post M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J. Clin. Invest. 105:2000;577-587.
6. Clark D. E., Smith S. K., Licence D., Evans A. L., Charnock-Jones D. S. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J. Endocrinol. 159:1998;459-467.
7. Cockman M. E., Masson N., Mole D. R., Jaakkola P., Chang G.-W., Clifford S. C., Maher E. R., Pugh C. W., Ratcliffe P. J., Maxwell P. H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:2000;25733-25741.
8. Cross J. C., Werb Z., Fisher S. J. Implantation and the placenta: key pieces of the development puzzle. Science. 266:1994;1508-1518.
9. Damsky C. H., Fisher S. J. Trophoblast pseudo-vasculogenesis: Faking it with endothelial adhesion receptors. Curr. Opin. Cell. Biol. 10:1998;660-666.
10. Damsky C. H., Fitzgerald M. L., Fisher S. J. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. J. Clin. Invest. 89:1992;210-222.
11. Damsky C. H., Librach C., Lim K. H., Fitzgerald M. L., McMaster M. T., Janatpour M., Zhou Y., Logan S. K., Fisher S. J. Integrin switching regulates normal trophoblast invasion. Development. 120:1994;3657-3666.
12. Dimri G. P., Testori A., Acosta M., Campisi J. Replicative senescence, aging and growth-regulatory transcription factors. Biol. Signals. 5:1996;154-162.
13. Enders A. C. Cytodifferentiation of trophoblast in the anchoring villi and trophoblastic shell in the first half of gestation in the macaque. Microsc. Res. Tech. 38:1997;3-20.
14. Genbacev O., Jensen K. D., Powlin S. S., Miller R. K. In vitro differentiation and ultrastructure of human extravillous trophoblast (EVT) cells. Placenta. 14:1993;463-475.
15. Genbacev O., Joslin R., Damsky C. H., Polliotti B. M., Fisher S. J. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J. Clin. Invest. 97:1996;540-550.
16. Genbacev O., Miller R. K. Three-dimensional culture of placental villous tissue explants: An in vitro model for peri-implantation. Methods Toxicol. 3:1993;205-244.
17. Genbacev O., Schubach S. A., Miller R. K. Villous culture of first trimester human placenta-model to study extravillous trophoblast (EVT) differentiation. Placenta. 13:1992;439-461.
18. Genbacev O., Zhou Y., Ludlow J. W., Fisher S. J. Regulation of human placental development by oxygen tension. Science. 277:1997;1669-1672.
19. Gnarra J. R., Ward J. M., Porter F. D., Wagner J. R., Devor D. E., Grinberg A., Emmert-Buck M. R., Westphal H., Klausner R. D., Linehan W. M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA. 94:1997;9102-9107.
20. Guillemot F., Nagy A., Auerbach A., Rossant J., Joyner A. L. Essential role of Mash-2 in extraembryonic development. Nature. 371:1994;333-336.
21. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
22. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12:1998;149-162.
23. Janatpour M. J., McMaster M. T., Genbacev O., Zhou Y., Dong J. Y., Cross J. C., Israel M. A., Fisher S. J. Id-2 regulates critical aspects of human cytotrophoblast differentiation, invasion and migration. Development. 127:2000;549-558.
24. Kaelin W. G. Jr. Cancer: Many vessels, faulty gene [news; comment]. Nature. 399:1999;203-204.
25. Kibel A., Iliopoulos O., DeCaprio J. A., Kaelin W. G. Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 269:1995;1444-1446.
26. Koochekpour S., Jeffers M., Wang P. H., Gong C., Taylor G. A., Roessler L. M., Stearman R., Vasselli J. R., Stetler-Stevenson W. G., Kaelin W. G. Jr., Linehan W. M., Klausner R. D., Gnarra J. R., Vande Woude G. F. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 19:1999;5902-5912.
27. Kozak K. R., Abbott B., Hankinson O. ARNT-deficient mice and placental differentiation. Dev. Biol. 191:1997;297-305.
28. Lee S., Neumann M., Stearman R., Stauber R., Pause A., Pavlakis G. N., Klausner R. D. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19:1999;1486-1497.
29. Librach C. L., Werb Z., Fitzgerald M. L., Chiu K., Corwin N. M., Esteves R. A., Grobelny D., Galardy R., Damsky C. H., Fisher S. J. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J. Cell Biol. 113:1991;437-449.
30. Linehan W. M., Lerman M. I., Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 273:1995;564-570.
31. Lonergan K. M., Iliopoulos O., Ohh M., Kamura T., Conaway R. C., Conaway J. W., Kaelin W. G. Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18:1998;732-741.
32. Maher E. R., Kaelin W. G. Jr. von Hippel-Lindau disease. Medicine (Baltimore). 76:1997;381-391.
33. Maxwell P. H., Wiesener M. S., Chang G. W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
34. Melmon K., Rosen S. Lindau's disease. Am. J. Med. 36:1964;595-617.
35. Nasu K., Zhou Y., McMaster M. T., Fisher S. J. Upregulation of human cytotrophoblast invasion by hepatocyte growth factor. J. Reprod. Fertil. Suppl. 55:2000;73-80.
36. Ohh M., Park C. W., Ivan M., Hoffman M. A., Kim T. Y., Huang L. E., Pavletich N., Chau V., Kaelin W. G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:2000;423-277.
37. Ohh M., Yauch R. L., Lonergan K. M., Whaley J. M., Stemmer-Rachamimov A. O., Louis D. N., Gavin B. J., Kley N., Kaelin W. G. Jr., Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1:1998;959-968.
38. Pause A., Lee S., Lonergan K. M., Klausner R. D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA. 95:1998;993-998.
39. Rodesch F., Simon P., Donner C., Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet. Gynecol. 80:1992;283-285.
40. Ryan H. E., Lo J., Johnson R. S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
41. Semenza G. L. Perspectives on oxygen sensing. Cell. 98:1999;281-284.
42. Stebbins C. E., Kaelin W. G. Jr., Pavletich N. P. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science. 284:1999;455-461.
43. Tian H., Hammer R. E., Matsumoto A. M., Russell D. W., McKnight S. L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12:1998;3320-3324.
44. Tian H., McKnight S. L., Russell D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:1997;72-82.
45. Zbar B., Kaelin W., Maher E., Richard S. Third International Meeting on von Hippel-Lindau disease. Cancer Res. 59:1999;2251-2253.
46. Zhou Y., Damsky C. H., Chiu K., Roberts J. M., Fisher S. J. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J. Clin. Invest. 91:1993;950-960.